Liver Biopsy Market Research Report Information By Type (Percutaneous, Transjugular, Laparoscopic), Indication (Nonalcoholic Fatty Liver Disease, Chronic Hepatitis B Or C), End User (Hospitals & Clinics, Diagnostic Centers)-Forecast Till 2032

Liver Biopsy Market Overview

Liver Biopsy Market Size was valued at USD 0.84 Billion in 2023. The Liver Biopsy industry is projected to grow from USD 0.92 Billion in 2024 to USD 1.67 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.92% during the forecast period (2024 - 2032). Liver biopsy is a procedure for obtaining samples from kidney tissue for analysis. Liver biopsy is used to diagnose various liver diseases such as nonalcoholic fatty liver disease, chronic hepatitis B or C, autoimmune hepatitis, and alcoholic liver disease. Along with the diagnosis it is also used to monitor the effect of treatment and determine whether the kidney transplant is working well or not. It consists of mainly two types; percutaneous biopsy, transjugular, and laparoscopic. In a percutaneous biopsy, a needle is inserted into the kidney through the skin, while in the surgical biopsy, an incision is made in the skin near the liver to take a tissue sample for examination.

According to the Centers for Disease Control and Prevention (CDC), 3.9 million adults were diagnosed with liver disease in the U.S.

Increasing prevalence of liver diseases and increasing number of biopsy procedures and diseases are the major drivers for the growth of the the liver biopsy market. Furthermore, rising demand for new techniques for diagnosis of chronic and the need for better diagnostic and treatment methods drive the growth of the the liver biopsy market. Major players in the developed countries lead the global market by offering new products and services to the developing countries and emerging economies. However, the high cost of diagnostic devices and instruments may hinder the liver biopsy market growth during the forecast period.

Liver Biopsy Market Segment Insights

The global liver biopsy market is segmented on the basis of type, indication, and end user.

Liver Biopsy Diagnosis Insights

On the basis of diagnosis, the liver biopsy market is segmented into percutaneous, transjugular, and laparoscopic biopsy.

Liver Biopsy Indication Insights

On the basis of indication, the liver biopsy market is segmented into the nonalcoholic fatty liver disease, chronic hepatitis B or C, autoimmune hepatitis, alcoholic liver disease, and others.

Liver Biopsy End User Insights

Based on the end user, the liver biopsy market is segmented into hospitals & clinics, tertiary care centers, urology centers, and others.

Liver Biopsy Market Regional Analysis

The Americas liver biopsy market is expected to exhibit extensive growth owing to technological advancement in the healthcare sector and increasing number of patient population suffering from liver diseases such as alcoholic liver disease and the high healthcare spending, and increasing government support for research & development will further boost the the liver biopsy market growth. Additionally, liver disease is one of the major cause of mortality and morbidity in the Americas, thus boosting the market growth. As per the data from (CDC), in 2016, 38,170 deaths occurred due to liver diseases in the U.S. Additionally, 6.10% of the adults were diagnosed with liver diseases in the U.S. alone. As per the World Health Organisation (WHO), about 35 million people in the world die of chronic diseases, while 46% of the mortality is due to chronic diseases. According to National statistics in the U.K, liver diseases is the fifth most common cause of death across the globe. Liver diseases are the second leading cause of mortality amongst all digestive diseases in the U.S.

In Europe, Germany, France, and the U.K are the major markets for liver biopsy. The market growth in the European region is attributed to increased use of diagnostic services in tertiary care centers, research and development activities in the field of chronic disease diagnostics, and the emergence of new market players in the medical device industry. 

Asia Pacific is expected to be the fastest growing kidney biopsy market across the globe owing to the vast progress of healthcare industries in major economies such as China, Japan, and India along with rising prevalence of chronic diseases such as chronic hepatitis B or C, and alcoholic liver disease. Japan holds a major share of the regional market due to the availability of technology, increasing healthcare spending, and increasing government initiatives for research. India is the hub of the patient population with various chronic diseases in the Asia Pacific region exhibiting extensive growth opportunities in the market. Rapidly developing healthcare technology sector and increasing healthcare expenditure also drive the the liver biopsy market. Furthermore, increasing demand for quality devices in the healthcare is expected to boost the use of advanced equipment, which, in turn, may speed up the growth of the market in the region.

The Middle East & Africa hold the least share of the global market due to limited availability of medical facilities. The United Arab Emirates, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market whereas, the African region is expected to witness a moderate growth.

Liver Biopsy Market Key Players

• Becton, Dickinson and Company,


• MDxHealth,


• Veran medical,


• Medtronic,


• Argon Medical Devices, Inc.,


• Mauna Kea Technologies,


• Boston Scientific Corporation,


• Intact Medical Corp., 


• C. R. Bard, Inc.,


• Leica Biosystems,


• Cook Medical,


• RI.MOS.,


• Hologic, Inc.,


• Sterylab,


• INRAD Inc.,


• Fujifilm Medical Systems, and


• Others.

 Intended Audience

• 
  

  Research and Development (R&D) Companies

  
  


• 
  

  Ambulatory Care Centers

  
  


• 
  

  Academic Institutes and Universities

  
  


• 
  

  Biotechnology Companies

  
  


• 
  

  Medical Device Manufacturers

  
  


• 
  

  Medical Device Suppliers

  
  


• 
  

  Market Research and Consulting Service Providers

  
  


• 
  

  Potential Investors